Home > Neurology > MS Virtual 2020 > Treatment Strategies and Results > Less thalamic atrophy in patients initiating ocrelizumab earlier

Less thalamic atrophy in patients initiating ocrelizumab earlier


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual
In the open-label extension (OLE) of the phase 3 trials OPERA I/OPERA II and ORATORIO, patients with relapsing and primary progressive MS who were initially randomised to ocrelizumab experienced less thalamic volume loss than those initiating ocrelizumab later [1]. Baseline thalamic volume may predict confirmed disability progression (CDP) and CDP-9-Hole Peg Test (9HPT) score in relapsing MS. Thalamic atrophy occurs early and consistently over the course of MS, at a rate that is faster than in healthy controls. MS has both a direct effect on the thalamus by neuronal loss, and an indirect effect due to axonal transection in lesions which affects afferent and efferent pro...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on